Media
Press releases
02Aug
Hansa Biopharma announces reimbursement in the Netherlands of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
15Jul
Regulatory press release
Hansa Biopharma interim report Jan-June 2021
09Jul
Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation
Media assets
Executive Leadership Team
Dr Christian Kjellman
Senior Vice President, Chief Scientific Officer, Research and Development
